2023
Efficacy and Safety of Hyperbaric Oxygen Therapy in Fistulizing Crohn’s Disease
Dokmak A, Sweigart B, Orekondy N, Jangi S, Weinstock J, Hamdeh S, Kochar G, Shen B, Levy A. Efficacy and Safety of Hyperbaric Oxygen Therapy in Fistulizing Crohn’s Disease. Journal Of Clinical Gastroenterology 2023, 58: 120-130. PMID: 37682003, DOI: 10.1097/mcg.0000000000001905.Peer-Reviewed Original ResearchConceptsHyperbaric oxygen therapySystematic reviewSafety of hyperbaric oxygen therapyHyperbaric oxygen therapy sessionsFistulizing Crohn's diseaseClinical responseCochrane Handbook guidelinesRisk of biasCrohn's diseaseFistulizing CDRandomized controlled trialsWeb of ScienceOxygen therapyStudy biasMeta-analysesCochrane Library databasesMeta-regressionEffective treatment optionBenefits of hyperbaric oxygen therapyControlled trialsRegulate inflammatory pathwaysMeta-analysisInflammatory bowel diseaseIncreased tissue oxygen levelsFistula typeEFFICACY AND SAFETY OF HYPERBARIC OXYGEN THERAPY IN FISTULIZING CROHN’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Dokmak A, Sweigart B, Orekondy N, Jangi S, Hamdeh S, Weinstock J, Kochar G, Shen B, Levy A. EFFICACY AND SAFETY OF HYPERBARIC OXYGEN THERAPY IN FISTULIZING CROHN’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. Gastroenterology 2023, 164: s81. DOI: 10.1053/j.gastro.2023.03.152.Peer-Reviewed Original ResearchPredictors and Etiologies of Clinical Relapse Among Patients With Ulcerative Colitis in Deep Remission
Zeina T, Gandhi S, Mittal A, Levy A, Weinstock J, Singh S, Jangi S. Predictors and Etiologies of Clinical Relapse Among Patients With Ulcerative Colitis in Deep Remission. Journal Of Clinical Gastroenterology 2023, 58: 195-199. PMID: 36753459, PMCID: PMC10406966, DOI: 10.1097/mcg.0000000000001834.Peer-Reviewed Original ResearchConceptsEtiology of relapseRisk of relapseCumulative risk of relapseRisk of clinical relapseDeep remissionDiscontinuation of therapyClinical relapseUlcerative colitisNormalization of C-reactive proteinCumulative riskRetrospective cohort studyC-reactive proteinTufts Medical CenterEndoscopic remissionHistological remissionRelapse riskIdentified etiologyRemissionRelapseCohort studyPatientsHistological changesMedical recordsColitisElectronic medical recordsEFFICACY AND SAFETY OF HYPERBARIC OXYGEN THERAPY IN FISTULIZING CROHN'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Dokmak A, Sweigart B, Orekondy N, Jangi S, Hamdeh S, Weinstock J, Kochar G, Shen B, Levy A. EFFICACY AND SAFETY OF HYPERBARIC OXYGEN THERAPY IN FISTULIZING CROHN'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. Inflammatory Bowel Diseases 2023, 29: s63-s63. DOI: 10.1093/ibd/izac247.121.Peer-Reviewed Original ResearchHyperbaric oxygen therapy sessionsHyperbaric oxygen therapyInflammatory bowel diseaseClinical responseClinical remissionRandomized controlled trialsPartial responseRectovaginal fistulaFistulizing CDResponse to HBOTCrohn's diseaseControlled trialsLow adverse event ratesSystematic reviewClinical response rateOutcome dataFistulizing Crohn's diseaseAdjunctive hyperbaric oxygen therapyClosure of fistulaMeta-analysisCochrane Library databasesAdverse event ratesCessation of drainagePotential clinical benefitCase-control study
2022
Adjunctive Hyperbaric Oxygen Therapy for High Risk Peristomal Pyoderma Gangrenosum
Zeina T, Levy A. Adjunctive Hyperbaric Oxygen Therapy for High Risk Peristomal Pyoderma Gangrenosum. Digestive Diseases And Sciences 2022, 67: 4597-4598. PMID: 35989384, DOI: 10.1007/s10620-022-07646-x.Peer-Reviewed Original ResearchSa1561: PREDICTORS OF CLINICAL RELAPSE AMONG PATIENTS WITH ULCERATIVE COLITIS IN ENDO-HISTOLOGIC REMISSION
Zeina T, Gandhi S, Mittal A, Levy A, Weinstock J, Jangi S. Sa1561: PREDICTORS OF CLINICAL RELAPSE AMONG PATIENTS WITH ULCERATIVE COLITIS IN ENDO-HISTOLOGIC REMISSION. Gastroenterology 2022, 162: s-414. DOI: 10.1016/s0016-5085(22)60988-0.Peer-Reviewed Original ResearchNatural History of New-onset Inflammatory Bowel Disease Among Patients With Multiple Sclerosis
Gandhi S, Zelman S, De Armas R, Hemond C, Levy A, Singh S, Korzenik J, Jangi S. Natural History of New-onset Inflammatory Bowel Disease Among Patients With Multiple Sclerosis. Inflammatory Bowel Diseases 2022, 28: 1614-1617. PMID: 35348692, PMCID: PMC9527605, DOI: 10.1093/ibd/izac053.Peer-Reviewed Original ResearchPREDICTORS OF CLINICAL RELAPSE AMONG PATIENTS WITH ULCERATIVE COLITIS IN ENDO-HISTOLOGIC REMISSION
Zeina T, Gandhi S, Mittal A, Levy A, Weinstock J, Jangi S. PREDICTORS OF CLINICAL RELAPSE AMONG PATIENTS WITH ULCERATIVE COLITIS IN ENDO-HISTOLOGIC REMISSION. Inflammatory Bowel Diseases 2022, 28: s47-s48. DOI: 10.1093/ibd/izac015.073.Peer-Reviewed Original ResearchRisk of relapseCumulative risk of relapseRisk of clinical relapseDeep remissionHistological remissionClinical relapseUlcerative colitisDisease durationEndoscopic remissionCumulative riskMedian follow-up timeDuration of follow-upPredictive of clinical relapseMedian disease durationFollow-up timeRetrospective cohort studyPredictors of relapseMayo endoscopic scoreTufts Medical CenterPatient-reported outcomesMedian ageRelapse rateRelapse riskEndoscopic scoreElectronic medical records
2019
Sa1541 – Metabolomic Analysis of Primary Sclerosing Cholangitis Reveals a Distinct Fingerprint
Levy A, Pratt D, Merker A, Quevedo S, Snapper S, Korzenik J. Sa1541 – Metabolomic Analysis of Primary Sclerosing Cholangitis Reveals a Distinct Fingerprint. Gastroenterology 2019, 156: s-346. DOI: 10.1016/s0016-5085(19)37696-6.Peer-Reviewed Original Research